• GRI Bio highlighted its idiopathic pulmonary fibrosis drug candidate GRI-0621 in a “Why Now” on-demand investor webcast.
• New study results were not released; data are scheduled for presentation at the 2026 European Respiratory Society Congress on Sept. 5-9.
• Management framed GRI-0621 as a once-daily oral therapy targeting inflammation, fibrosis, tissue repair to support a differentiated approach in IPF.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gri Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270901PRIMZONEFULLFEED9816850) on August 27, 2026, and is solely responsible for the information contained therein.